Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein-glucosylgalactosylhydroxylysine glucosidase (PGGHG) is an enzyme encoded by the ATHL1 gene that belongs to the glycoside hydrolase family 65 (GH65)[1][3][5]. It specifically cleaves glucose from the disaccharide α-d-glucopyranosyl-(1→2)-β-d-galactopyranose units attached to hydroxylysine residues of collagen and collagen-like proteins[1][3]. This activity is a key step in collagen modification and metabolism, with important roles in the structure and function of the extracellular matrix[2][3][5]. PGGHG is implicated in diseases such as osteogenesis imperfecta type V and osteoporosis due to its involvement in collagen processing[5]. The enzyme is predicted to localize mostly in the cytosol and is essential for proper carbohydrate metabolic processes, particularly those influencing collagen secretion, fibril alignment, and tissue homeostasis[5][6]. Site-directed mutagenesis has identified several critical carboxyl residues (Asp301, Glu430, and Glu574) as part of its catalytic site[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein-glucosylgalactosylhydroxylysine glucosidase (PGGHG).